{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T05:08:27Z","timestamp":1793941707063,"version":"4.8.0"},"reference-count":256,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100014718","name":"Innovative Research Group Project of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014718","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82304285"],"award-info":[{"award-number":["82304285"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008048","name":"Nanjing University","doi-asserted-by":"publisher","award":["013038023001P"],"award-info":[{"award-number":["013038023001P"]}],"id":[{"id":"10.13039\/501100008048","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.ejmech.2025.118191","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T01:54:34Z","timestamp":1758765274000},"page":"118191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Tubulin-based dual-target compounds and protein degraders for cancer therapy\u2014An updated review (2021-present)"],"prefix":"10.1016","volume":"301","author":[{"given":"Shijia","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhouyan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziwei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanyan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cheng","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chenglei","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jichao","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2025.118191_bib1","first-page":"10","article-title":"Cancer statistics","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118191_bib2","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118191_bib3","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib4","doi-asserted-by":"crossref","first-page":"9663","DOI":"10.1007\/s11033-023-08809-3","article-title":"Cancer treatment therapies: traditional to modern approaches to combat cancers","volume":"50","author":"Kaur","year":"2023","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ejmech.2025.118191_bib5","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1038\/s12276-022-00864-3","article-title":"Molecular targeted therapy for anticancer treatment","volume":"54","author":"Min","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib6","first-page":"27","article-title":"Acquired resistance to molecularly targeted therapies for cancer","volume":"8","author":"Stubbs","year":"2025","journal-title":"Cancer Drug Resist"},{"key":"10.1016\/j.ejmech.2025.118191_bib7","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117278","article-title":"Insights into tumor-derived exosome inhibition in cancer therapy","volume":"285","author":"Tang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib8","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1080\/17568919.2024.2424149","article-title":"Insights into direct KRAS inhibition strategies for cancer treatment","volume":"16","author":"Li","year":"2024","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib9","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1186\/s12964-024-01607-9","article-title":"Potentials and future perspectives of multi-target drugs in cancer treatment: the next generation anti-cancer agents","volume":"22","author":"Doostmohammadi","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ejmech.2025.118191_bib10","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.3390\/cancers17071211","article-title":"Tumor treating fields and combination therapy in management of brain oncology","volume":"17","author":"Liu","year":"2025","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118191_bib11","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1021\/acs.jmedchem.3c02133","article-title":"Combination therapy and dual-target inhibitors based on LSD1: new emerging tools in cancer therapy","volume":"67","author":"Shen","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117453","article-title":"Research progress and perspectives of dual-target inhibitors","volume":"289","author":"Pang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117289","article-title":"Research progress in bifunctional small molecules for cancer immunotherapy","volume":"286","author":"Cheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117235","article-title":"Overview of the epigenetic\/cytotoxic dual-target inhibitors for cancer therapy","volume":"285","author":"Liang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib15","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116543","article-title":"Dual-target inhibitors of colchicine binding site for cancer treatment","volume":"274","author":"Lu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib16","article-title":"Microtubule organization is essential for maintaining cellular morphology and function","volume":"2022","author":"Huang","year":"2022","journal-title":"Oxid. Med. Cell. Longev."},{"key":"10.1016\/j.ejmech.2025.118191_bib17","doi-asserted-by":"crossref","first-page":"889","DOI":"10.2174\/1389450124666230731094837","article-title":"Microtubules and cell division: potential pharmacological targets in cancer therapy","volume":"24","author":"Sebastian","year":"2023","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118191_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2024.108726","article-title":"Microtubule dynamics in cancer metastasis: Harnessing the underappreciated potential for therapeutic interventions","volume":"263","author":"Mangaonkar","year":"2024","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-3-031-58311-7_1","article-title":"Microtubule-targeting agents: disruption of the cellular cytoskeleton as a backbone of ovarian cancer therapy","volume":"1452","author":"Danziger","year":"2024","journal-title":"Adv. Exp. Med. Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.108116","article-title":"Dual-targeting inhibitors involving tubulin for the treatment of cancer","volume":"156","author":"Yakkala","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib21","doi-asserted-by":"crossref","first-page":"5650","DOI":"10.3390\/cancers13225650","article-title":"Microtubule targeting agents in disease: classic drugs, novel roles","volume":"13","author":"Wordeman","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118191_bib22","doi-asserted-by":"crossref","first-page":"7963","DOI":"10.1021\/acs.jmedchem.1c00100","article-title":"Recent progress on tubulin inhibitors with dual targeting capabilities for cancer therapy","volume":"64","author":"Shuai","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib23","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/nrc2803","article-title":"Microtubules and resistance to tubulin-binding agents","volume":"10","author":"Kavallaris","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2025.118191_bib24","article-title":"Paclitaxel resistance in breast cancer: current challenges and recent advanced therapeutic strategies","volume":"43","author":"Abouzeid","year":"2025","journal-title":"Cancer Treat. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118191_bib25","article-title":"\u03b2III-tubulin overexpression in cancer: causes, consequences, and potential therapies","volume":"1876","author":"Kanakkanthara","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2025.118191_bib26","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2023.1157306","article-title":"Chemotherapeutic properties and side-effects associated with the clinical practice of terpene alkaloids: paclitaxel, docetaxel, and cabazitaxel","volume":"14","author":"Sousa-Pimenta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.drudis.2020.11.033","article-title":"Microtubule-targeting agents and neurodegeneration","volume":"26","author":"Boiarska","year":"2021","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118191_bib28","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3390\/ph13010008","article-title":"Colchicine-binding site inhibitors from chemistry to clinic: a review","volume":"13","author":"McLoughlin","year":"2020","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118191_bib29","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173692","article-title":"Vascular disrupting agents in cancer therapy","volume":"891","author":"Smolarczyk","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib30","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1016\/j.canlet.2017.06.032","article-title":"Suppression of angiogenesis and tumour progression by combretastatin and derivatives","volume":"403","author":"Sherbet","year":"2017","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116205","article-title":"Novel 4-aryl-4H-chromene derivative displayed excellent in vivo anti-glioblastoma efficacy as the microtubule-targeting agent","volume":"267","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114744","article-title":"Development of [1,2]oxazoloisoindoles tubulin polymerization inhibitors: further chemical modifications and potential therapeutic effects against lymphomas","volume":"243","author":"Barreca","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib33","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108676","article-title":"Discovery of novel combretastatin A4 derivatives as a microtubule targeting agent capable of inducing HepG-2 cell apoptosis via the mitochondria and ER stress mediated pathway","volume":"163","author":"Huang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib34","doi-asserted-by":"crossref","DOI":"10.3390\/ijms231810222","article-title":"The new microtubule-targeting agent SIX2G induces immunogenic cell death in multiple myeloma","volume":"23","author":"Grillone","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2025.108355","article-title":"Identification of selenium-containing benzamides as potent microtubule-targeting antitumor agents","volume":"159","author":"Jiang","year":"2025","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.113122","article-title":"Insight on [1,3]thiazolo[4,5-e]isoindoles as tubulin polymerization inhibitors","volume":"212","author":"Span\u00f2","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113590","article-title":"A comprehensive assessment of a new series of 5',6'-difluorobenzotriazole-acrylonitrile derivatives as microtubule targeting agents (MTAs)","volume":"222","author":"Riu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib38","article-title":"Combination of microtubule targeting agents with other antineoplastics for cancer treatment","volume":"1877","author":"Liang","year":"2022","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2025.118191_bib39","doi-asserted-by":"crossref","first-page":"500","DOI":"10.3390\/biomedicines9050500","article-title":"Paclitaxel-based chemotherapy targeting cancer stem cells from mono- to combination therapy","volume":"9","author":"Nawara","year":"2021","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118191_bib40","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1038\/s41388-021-01841-2","article-title":"Receptor tyrosine kinases and cancer: oncogenic mechanisms and therapeutic approaches","volume":"40","author":"Saraon","year":"2021","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118191_bib41","doi-asserted-by":"crossref","first-page":"17358","DOI":"10.1074\/jbc.M000966200","article-title":"Expression of oncogenic epidermal growth factor receptor family kinases induces paclitaxel resistance and alters beta-tubulin isotype expression","volume":"275","author":"Montgomery","year":"2000","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib42","doi-asserted-by":"crossref","first-page":"374","DOI":"10.3349\/ymj.2013.54.2.374","article-title":"Blockade of VEGFR-1 and VEGFR-2 enhances paclitaxel sensitivity in gastric cancer cells","volume":"54","author":"Hwang","year":"2013","journal-title":"Yonsei Med. J."},{"key":"10.1016\/j.ejmech.2025.118191_bib43","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1038\/jid.2008.37","article-title":"Microtubule-targeted drugs inhibit VEGF receptor-2 expression by both transcriptional and post-transcriptional mechanisms","volume":"128","author":"Meissner","year":"2018","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.ejmech.2025.118191_bib44","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-024-01899-w","article-title":"Therapeutic advances of targeting receptor tyrosine kinases in cancer","volume":"9","author":"Tomuleasa","year":"2024","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib45","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1007\/s00018-023-04729-4","article-title":"Receptor tyrosine kinase inhibitors in cancer","volume":"80","author":"Ebrahimi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib46","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1002\/med.21568","article-title":"Current advances of tubulin inhibitors as dual acting small molecules for cancer therapy","volume":"39","author":"Arnst","year":"2019","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118191_bib47","article-title":"A phase II clinical study on apatinib plus vinorelbine in refractory HER2-negative breast cancer and its metabolic implications of drug resistance","author":"Wu","year":"2024","journal-title":"Curr. Cancer Drug Targets"},{"key":"10.1016\/j.ejmech.2025.118191_bib48","article-title":"Efficacy and safety of apatinib plus docetaxel as the second or above line treatment in advanced nonsquamous NSCLC: a multi center prospective study","volume":"98","author":"Jiang","year":"2019","journal-title":"Medicine (Baltim.)"},{"key":"10.1016\/j.ejmech.2025.118191_bib49","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1097\/JTO.0b013e318258cf17","article-title":"Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation","volume":"7","author":"Tsai","year":"2012","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib50","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.107087","article-title":"Design of balanced dual-target inhibitors of EGFR and microtubule","volume":"143","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib51","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104633","article-title":"Insights of 8-hydroxyquinolines: a novel target in medicinal chemistry","volume":"108","author":"Gupta","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib52","doi-asserted-by":"crossref","first-page":"11617","DOI":"10.1039\/D5RA01280E","article-title":"Excavating medicinal virtues of chalcones to illuminate a new scope in cancer chemotherapy","volume":"15","author":"T","year":"2025","journal-title":"RSC Adv."},{"key":"10.1016\/j.ejmech.2025.118191_bib53","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/14756366.2021.1976772","article-title":"A review on synthetic chalcone derivatives as tubulin polymerisation inhibitors","volume":"37","author":"Liu","year":"2022","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib54","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2023.106444","article-title":"Design, synthesis, cytotoxic activities, and molecular docking of chalcone hybrids bearing 8-hydroxyquinoline moiety with dual tubulin\/EGFR kinase inhibition","volume":"134","author":"Amin","year":"2023","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib55","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107679","article-title":"Discovery of novel amide derivatives against VEGFR-2\/tubulin with potent antitumor and antiangiogenic activity","volume":"151","author":"Liu","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib56","article-title":"Mechanisms of HDACs in cancer development","volume":"16","author":"Zhang","year":"2025","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ejmech.2025.118191_bib57","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s12032-022-01770-4","article-title":"Differential molecular mechanistic behavior of HDACs in cancer progression","volume":"39","author":"Singh","year":"2022","journal-title":"Med. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib58","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.3390\/cancers12061664","article-title":"Roles of histone deacetylases and inhibitors in anticancer therapy","volume":"12","author":"Verza","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118191_bib59","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117022","article-title":"Tubulin\/HDAC dual-target inhibitors: insights from design strategies, SARs, and therapeutic potential","volume":"281","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib60","first-page":"376","article-title":"Cancer epigenetics in clinical practice","volume":"73","author":"Davalos","year":"2023","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.ejmech.2025.118191_bib61","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41420-024-01803-z","article-title":"Cancer epigenetics: from laboratory studies and clinical trials to precision medicine","volume":"10","author":"Yu","year":"2024","journal-title":"Cell Death Discov."},{"key":"10.1016\/j.ejmech.2025.118191_bib62","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/s12929-021-00721-x","article-title":"Recent developments in epigenetic cancer therapeutics: clinical advancement and emerging trends","volume":"28","author":"Nepali","year":"2021","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib63","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1016\/j.apsb.2023.02.007","article-title":"Targeting histone deacetylases for cancer therapy: trends and challenges","volume":"13","author":"Liang","year":"2023","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ejmech.2025.118191_bib64","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1186\/s40001-024-02108-8","article-title":"Histone deacetylase inhibitors for leukemia treatment: current status and future directions","volume":"29","author":"Hosseini","year":"2024","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib65","doi-asserted-by":"crossref","first-page":"341","DOI":"10.3390\/ph18030341","article-title":"Recent advancements in the development of HDAC\/tubulin dual-targeting inhibitors","volume":"18","author":"Tran","year":"2025","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118191_bib66","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113825","article-title":"Combining histone deacetylase inhibitors (HDACis) with other therapies for cancer therapy","volume":"226","author":"Zhou","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib67","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.dnarep.2014.04.011","article-title":"Regulation of SIRT2-dependent \u03b1-tubulin deacetylation by cellular NAD levels","volume":"23","author":"Skoge","year":"2014","journal-title":"DNA Repair"},{"key":"10.1016\/j.ejmech.2025.118191_bib68","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1016\/j.canlet.2009.01.040","article-title":"Histone deacetylase inhibitors that target tubulin","volume":"280","author":"Schemies","year":"2009","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib69","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/417455a","article-title":"HDAC6 is a microtubule-associated deacetylase","volume":"417","author":"Hubbert","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2025.118191_bib70","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1038\/emboj.2009.317","article-title":"CYLD negatively regulates cell-cycle progression by inactivating HDAC6 and increasing the levels of acetylated tubulin","volume":"29","author":"Wickstr\u00f6m","year":"2010","journal-title":"EMBO J."},{"key":"10.1016\/j.ejmech.2025.118191_bib71","doi-asserted-by":"crossref","first-page":"22516","DOI":"10.1074\/jbc.M113.489328","article-title":"Inhibition of HDAC6 deacetylase activity increases its binding with microtubules and suppresses microtubule dynamic instability in MCF-7 cells","volume":"288","author":"Asthana","year":"2013","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib72","doi-asserted-by":"crossref","first-page":"480","DOI":"10.2174\/1389557523666230717110255","article-title":"The development of HDAC and tubulin dual-targeting inhibitors for cancer therapy","volume":"24","author":"Nie","year":"2024","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib73","doi-asserted-by":"crossref","first-page":"1262","DOI":"10.1007\/s12094-022-02779-x","article-title":"Insights into the therapeutic potential of histone deacetylase inhibitor\/immunotherapy combination regimens in solid tumors","volume":"24","author":"Sedky","year":"2022","journal-title":"Clin. Transl. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib74","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s40001-025-02326-8","article-title":"Targeted intervention of tumor microenvironment with HDAC inhibitors and their combination therapy strategies","volume":"30","author":"Zhang","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib75","doi-asserted-by":"crossref","first-page":"14787","DOI":"10.1021\/acs.jmedchem.3c01385","article-title":"Development of first-in-class dual SIRT2\/HDAC6 inhibitors as molecular tools for dual inhibition of tubulin deacetylation","volume":"66","author":"Sinatra","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib76","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.add3243","article-title":"HDAC3 is critical in tumor development and therapeutic resistance in kras-mutant non-small cell lung cancer","volume":"9","author":"Eichner","year":"2023","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ejmech.2025.118191_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112171","article-title":"Histone deacetylase 3 (HDAC3) inhibitors as anticancer agents: a review","volume":"192","author":"Sarkar","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib78","doi-asserted-by":"crossref","first-page":"8447","DOI":"10.1021\/acs.jmedchem.1c00413","article-title":"Efficient synthesis and bioevaluation of novel dual tubulin\/histone deacetylase 3 inhibitors as potential anticancer agents","volume":"64","author":"Peng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib79","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1080\/07357907.2017.1364745","article-title":"Realizing the potential of vascular targeted therapy: the rationale for combining vascular disrupting agents and anti-angiogenic agents to treat cancer","volume":"35","author":"Siemann","year":"2017","journal-title":"Cancer Invest."},{"key":"10.1016\/j.ejmech.2025.118191_bib80","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1089\/dna.2019.4877","article-title":"The antiangiogenesis role of histone deacetylase inhibitors: their potential application to tumor therapy and tissue repair","volume":"39","author":"Deng","year":"2020","journal-title":"DNA Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib81","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1615\/CritRevOncog.2014012423","article-title":"Histone deacetylases and cancer-associated angiogenesis: current understanding of the biology and clinical perspectives","volume":"20","author":"Turtoi","year":"2015","journal-title":"Crit. Rev. Oncog."},{"key":"10.1016\/j.ejmech.2025.118191_bib82","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113316","article-title":"Discovery of novel N-benzylbenzamide derivatives as tubulin polymerization inhibitors with potent antitumor activities","volume":"216","author":"Zhu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib83","doi-asserted-by":"crossref","first-page":"11187","DOI":"10.1021\/acs.jmedchem.2c00681","article-title":"Discovery of a novel vascular disrupting agent inhibiting tubulin polymerization and HDACs with potent antitumor effects","volume":"65","author":"Zhu","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib84","doi-asserted-by":"crossref","first-page":"4538","DOI":"10.1021\/jm900321u","article-title":"Isocombretastatins A versus combretastatins A: the forgotten isoCA-4 isomer as a highly promising cytotoxic and antitubulin agent","volume":"52","author":"Messaoudi","year":"2009","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib85","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1016\/j.ejmech.2016.11.012","article-title":"Design, synthesis and anticancer properties of IsoCombretaQuinolines as potent tubulin assembly inhibitors","volume":"127","author":"Khelifi","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib86","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115529","article-title":"Synthesis and bioevaluation of novel stilbene-based derivatives as tubulin\/HDAC dual-target inhibitors with potent antitumor activities in vitro and in vivo","volume":"257","author":"Zhu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib87","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114573","article-title":"Design, synthesis and biological evaluation of quinoline-2-carbonitrile-based hydroxamic acids as dual tubulin polymerization and histone deacetylases inhibitors","volume":"240","author":"Hauguel","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib88","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2021.104988","article-title":"Synthesis and biological evaluation of new 2-methoxyestradiol derivatives: potent inhibitors of angiogenesis and tubulin polymerization","volume":"113","author":"Sun","year":"2021","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.105625","article-title":"2-methoxydiol derivatives as new tubulin and HDAC dual-targeting inhibitors, displaying antitumor and antiangiogenic response","volume":"120","author":"Sun","year":"2022","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib90","doi-asserted-by":"crossref","first-page":"1688","DOI":"10.1021\/jm970644q","article-title":"Antineoplastic agents. 379. Synthesis of phenstatin phosphate","volume":"41","author":"Pettit","year":"1998","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113790","article-title":"Discovery of novel tubulin\/HDAC dual-targeting inhibitors with strong antitumor and antiangiogenic potency","volume":"225","author":"Wang","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib92","doi-asserted-by":"crossref","first-page":"10329","DOI":"10.1021\/acs.jmedchem.6b01268","article-title":"Potent antitumor activities and structure basis of the chiral \u03b2-lactam bridged analogue of combretastatin A-4 binding to tubulin","volume":"59","author":"Zhou","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2023.117437","article-title":"Discovery of chiral 1,4-diarylazetidin-2-one-based hydroxamic acid derivatives as novel tubulin polymerization inhibitors with histone deacetylase inhibitory activity","volume":"92","author":"Tang","year":"2023","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib94","doi-asserted-by":"crossref","first-page":"9461","DOI":"10.1074\/jbc.RA117.001658","article-title":"The compound millepachine and its derivatives inhibit tubulin polymerization by irreversibly binding to the colchicine-binding site in \u03b2-tubulin","volume":"293","author":"Yang","year":"2018","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib95","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107624","article-title":"Design and bio-evaluation of novel millepachine derivatives targeting tubulin colchicine binding site for treatment of osteosarcoma","volume":"151","author":"Geng","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib96","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.bbrc.2023.09.044","article-title":"A review on millepachine and its derivatives as potential multitarget anticancer agents","volume":"681","author":"Rampogu","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ejmech.2025.118191_bib97","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116301","article-title":"Design and biological evaluation of dual tubulin\/HDAC inhibitors based on millepachine for treatment of prostate cancer","volume":"268","author":"Xie","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib98","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2020.112618","article-title":"Discovery of tertiary amide derivatives incorporating benzothiazole moiety as anti-gastric cancer agents in vitro via inhibiting tubulin polymerization and activating the hippo signaling pathway","volume":"203","author":"Song","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib99","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2022.115070","article-title":"A novel aromatic amide derivative SY-65 co-targeted tubulin and histone deacetylase 1 with potent anticancer activity in vitro and in vivo","volume":"201","author":"Li","year":"2022","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib100","article-title":"PARP1: a comprehensive review of its mechanisms, therapeutic implications and emerging cancer treatments","volume":"1880","author":"Concei\u00e7\u00e3o","year":"2025","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"key":"10.1016\/j.ejmech.2025.118191_bib101","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2022.106529","article-title":"Selective PARP1 inhibitors, PARP1-based dual-target inhibitors, PROTAC PARP1 degraders, and prodrugs of PARP1 inhibitors for cancer therapy","volume":"186","author":"Peng","year":"2022","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib102","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1073\/pnas.1416418112","article-title":"Microtubule-targeting agents augment the toxicity of DNA-damaging agents by disrupting intracellular trafficking of DNA repair proteins","volume":"112","author":"Poruchynsky","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejmech.2025.118191_bib103","doi-asserted-by":"crossref","first-page":"30773","DOI":"10.18632\/oncotarget.5040","article-title":"Small molecule inhibition of the CHFR-PARP1 interaction as novel approach to overcome intrinsic taxane resistance in cancer","volume":"6","author":"Brodie","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118191_bib104","doi-asserted-by":"crossref","first-page":"12975","DOI":"10.1074\/jbc.M111.321828","article-title":"CHFR protein regulates mitotic checkpoint by targeting PARP-1 protein for ubiquitination and degradation","volume":"287","author":"Kashima","year":"2012","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib105","first-page":"2649","article-title":"AMXI-5001, a novel dual parp1\/2 and microtubule polymerization inhibitor for the treatment of human cancers","volume":"10","author":"Lemjabbar-Alaoui","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib106","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1021\/acs.jnatprod.9b01285","article-title":"Natural products as sources of new drugs over the nearly four decades from 01\/1981 to 09\/2019","volume":"83","author":"Newman","year":"2020","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2025.118191_bib107","first-page":"195","article-title":"Progress in approved drugs from natural product resources","volume":"22","author":"Luo","year":"2024","journal-title":"Chin. J. Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib108","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116126","article-title":"Drug discovery and optimization based on the co-crystal structure of natural product with target","volume":"266","author":"Chen","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib109","doi-asserted-by":"crossref","first-page":"4660","DOI":"10.1002\/ptr.7099","article-title":"Natural products: a lead for drug discovery and development","volume":"35","author":"Chopra","year":"2021","journal-title":"Phytother Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib110","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.fitote.2015.04.012","article-title":"Insights into drug discovery from natural products through structural modification","volume":"103","author":"Chen","year":"2015","journal-title":"Fitoterapia"},{"key":"10.1016\/j.ejmech.2025.118191_bib111","doi-asserted-by":"crossref","DOI":"10.1080\/14756366.2023.2276665","article-title":"Flavone-based dual PARP-tubulin inhibitor manifesting efficacy against endometrial cancer","volume":"38","author":"Sharma","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib112","doi-asserted-by":"crossref","first-page":"333","DOI":"10.2174\/1568026621666211129140958","article-title":"Molecular modeling techniques applied to the design of multitarget drugs: methods and applications","volume":"22","author":"Castro","year":"2022","journal-title":"Curr. Top. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib113","doi-asserted-by":"crossref","DOI":"10.1016\/j.drudis.2024.104046","article-title":"Toward structure-multiple activity relationships (SMARts) using computational approaches: a polypharmacological perspective","volume":"29","author":"L\u00f3pez-L\u00f3pez","year":"2024","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.ejmech.2025.118191_bib114","doi-asserted-by":"crossref","first-page":"15702","DOI":"10.1021\/acs.jmedchem.1c00932","article-title":"Discovery of a dual tubulin and poly(ADP-ribose) polymerase-1 inhibitor by structure-based pharmacophore modeling, virtual screening, molecular docking, and biological evaluation","volume":"64","author":"Zheng","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib115","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1080\/17568919.2025.2507564","article-title":"Recent advances and future perspectives in small molecule JAK2 inhibitors","volume":"17","author":"Yasir","year":"2025","journal-title":"Future Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fcell.2022.942053","article-title":"JAK2 alterations in acute lymphoblastic leukemia: molecular insights for superior precision medicine strategies","volume":"10","author":"Downes","year":"2022","journal-title":"Front. Cell Dev. Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib117","doi-asserted-by":"crossref","first-page":"7153","DOI":"10.1021\/bi700101n","article-title":"Identification of tubulin as a substrate of JAK2 tyrosine kinase and its role in JAK2-dependent signaling","volume":"46","author":"Ma","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118191_bib118","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0158440","article-title":"MPT0B098, a microtubule inhibitor, suppresses JAK2\/STAT3 signaling pathway through modulation of SOCS3 stability in oral squamous cell carcinoma","volume":"11","author":"Peng","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2025.118191_bib119","doi-asserted-by":"crossref","first-page":"24304","DOI":"10.18632\/oncotarget.24368","article-title":"Ruxolitinib synergistically enhances the anti-tumor activity of paclitaxel in human ovarian cancer","volume":"9","author":"Han","year":"2018","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118191_bib120","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1007\/s00280-021-04245-x","article-title":"Phase I study of JAK1\/2 inhibitor ruxolitinib with weekly paclitaxel for the treatment of HER2-negative metastatic breast cancer","volume":"87","author":"Lynce","year":"2021","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib121","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1007\/s00109-021-02138-3","article-title":"JAK2 regulates paclitaxel resistance in triple negative breast cancers","volume":"99","author":"Han","year":"2021","journal-title":"J. Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib122","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113629","article-title":"Design, synthesis and biological evaluation of indole-based [1,2,4]triazolo[4,3-a] pyridine derivatives as novel microtubule polymerization inhibitors","volume":"223","author":"Wu","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib123","doi-asserted-by":"crossref","first-page":"15006","DOI":"10.1021\/acs.jmedchem.3c01690","article-title":"Design, synthesis, and antitumor efficacy of substituted 2-amino[1,2,4]triazolopyrimidines and related heterocycles as dual inhibitors for microtubule polymerization and janus kinase 2","volume":"66","author":"Chen","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib124","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2024.1375905","article-title":"The aryl hydrocarbon receptor as a tumor modulator: mechanisms to therapy","volume":"14","author":"Chaudhry","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib125","doi-asserted-by":"crossref","first-page":"472","DOI":"10.3390\/cancers16030472","article-title":"The aryl hydrocarbon receptor: impact on the tumor immune microenvironment and modulation as a potential therapy","volume":"16","author":"Griffith","year":"2024","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118191_bib126","doi-asserted-by":"crossref","first-page":"11","DOI":"10.3892\/mmr.2023.13134","article-title":"Aryl hydrocarbon receptor: an emerging player in breast cancer pathogenesis and its potential as a drug target","volume":"29","author":"Chen","year":"2024","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2025.118191_bib127","doi-asserted-by":"crossref","first-page":"36061","DOI":"10.1074\/jbc.R800053200","article-title":"Endogenous functions of the aryl hydrocarbon receptor (AHR): intersection of cytochrome P450 1 (CYP1)-metabolized eicosanoids and AHR biology","volume":"283","author":"Nebert","year":"2008","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib128","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/j.bcp.2009.12.010","article-title":"Beta tubulin affects the aryl hydrocarbon receptor function via an Arnt-mediated mechanism","volume":"79","author":"Zhang","year":"2010","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib129","doi-asserted-by":"crossref","first-page":"12964","DOI":"10.1021\/acs.jmedchem.1c01099","article-title":"Discovery of novel anti-breast-cancer inhibitors by synergistically antagonizing microtubule polymerization and aryl hydrocarbon receptor expression","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib130","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.phrs.2015.01.003","article-title":"Src protein-tyrosine kinase structure, mechanism, and small molecule inhibitors","volume":"94","author":"Roskoski","year":"2015","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib131","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1023\/A:1023772912750","article-title":"Src family kinases in tumor progression and metastasis","volume":"22","author":"Summy","year":"2003","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.ejmech.2025.118191_bib132","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1186\/s13058-022-01596-y","article-title":"SRC kinase-mediated signaling pathways and targeted therapies in breast cancer","volume":"24","author":"Luo","year":"2022","journal-title":"Breast Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib133","doi-asserted-by":"crossref","first-page":"1786","DOI":"10.1038\/s41388-023-02701-x","article-title":"Functional roles of SRC signaling in pancreatic cancer: recent insights provide novel therapeutic opportunities","volume":"42","author":"Poh","year":"2023","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2025.118191_bib134","doi-asserted-by":"crossref","DOI":"10.1002\/cbdv.202300515","article-title":"Medicinal chemistry perspectives on recent advances in src kinase inhibitors as a potential target for the development of anticancer agents: biological profile, selectivity, structure-activity relationship","volume":"20","author":"Teli","year":"2023","journal-title":"Chem. Biodivers."},{"key":"10.1016\/j.ejmech.2025.118191_bib135","doi-asserted-by":"crossref","first-page":"3249","DOI":"10.3892\/mmr.2015.3784","article-title":"Dasatinib enhances antitumor activity of paclitaxel in ovarian cancer through src signaling","volume":"12","author":"Xiao","year":"2015","journal-title":"Mol. Med. Rep."},{"key":"10.1016\/j.ejmech.2025.118191_bib136","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.yexcr.2014.08.002","article-title":"Src inhibition potentiates antitumoral effect of paclitaxel by blocking tumor-induced angiogenesis","volume":"328","author":"Delle Monache","year":"2014","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib137","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1080\/15384047.2019.1579956","article-title":"Dasatinib can enhance paclitaxel and gemcitabine inhibitory activity in human pancreatic cancer cells","volume":"20","author":"Ma","year":"2019","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib138","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s10549-018-05100-z","article-title":"Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM\/2010-04 study","volume":"174","author":"Ocana","year":"2019","journal-title":"Breast Cancer Res. Treat."},{"key":"10.1016\/j.ejmech.2025.118191_bib139","doi-asserted-by":"crossref","first-page":"4704","DOI":"10.1021\/acs.jmedchem.8b00164","article-title":"Discovery of novel dual mechanism of action Src signaling and tubulin polymerization inhibitors (KX2-391 and KX2-361)","volume":"61","author":"Smolinski","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib140","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1007\/s00280-013-2079-z","article-title":"A phase 2 study of KX2-391, an oral inhibitor of Src kinase and tubulin polymerization, in men with bone-metastatic castration-resistant prostate cancer","volume":"71","author":"Antonarakis","year":"2013","journal-title":"Cancer Chemother. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib141","doi-asserted-by":"crossref","first-page":"8127","DOI":"10.1021\/acs.jmedchem.0c01961","article-title":"Design, synthesis, and bioactivity evaluation of dual-target inhibitors of tubulin and Src kinase guided by crystal structure","volume":"64","author":"Wang","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib142","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-biochem-030122-043917","article-title":"Structural mechanisms of topoisomerase-targeting drugs","volume":"94","author":"O'Donnell","year":"2025","journal-title":"Annu. Rev. Biochem."},{"key":"10.1016\/j.ejmech.2025.118191_bib143","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.3390\/ph16101456","article-title":"Prospects of topoisomerase inhibitors as promising anti-cancer agents","volume":"16","author":"Yakkala","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.118191_bib144","first-page":"421","article-title":"Topoisomerases and tubulin inhibitors: a promising combination for cancer treatment","volume":"3","author":"Rudolf","year":"2003","journal-title":"Curr. Med. Chem. Anti Cancer Agents"},{"key":"10.1016\/j.ejmech.2025.118191_bib145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejcb.2020.151075","article-title":"Microtubule-targeting agents and their impact on cancer treatment","volume":"99","author":"\u010cerm\u00e1k","year":"2020","journal-title":"Eur. J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib146","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/biom12121843","article-title":"Recent advances of tubulin inhibitors targeting the colchicine binding site for cancer therapy","volume":"12","author":"Hawash","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118191_bib147","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ygyno.2024.03.002","volume":"183","author":"Gass","year":"2024","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib148","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.3390\/biom12121843","article-title":"Recent advances of tubulin inhibitors targeting the colchicine binding site for cancer therapy","volume":"12","author":"Hawash","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118191_bib149","doi-asserted-by":"crossref","first-page":"2996","DOI":"10.1200\/JCO.2000.18.16.2996","article-title":"Phase I and pharmacologic study of docetaxel and irinotecan in advanced non-small-cell lung cancer","volume":"18","author":"Masuda","year":"2000","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib150","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/cncr.20238","article-title":"Phase I evaluation of docetaxel and topotecan for patients with advanced solid tumors","volume":"100","author":"Tsao","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.118191_bib151","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/j.bmcl.2006.12.034","article-title":"Novel pyridinyl and pyrimidinylcarbazole sulfonamides as antiproliferative agents","volume":"17","author":"Hu","year":"2007","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib152","doi-asserted-by":"crossref","first-page":"6218","DOI":"10.1158\/1078-0432.CCR-08-0550","article-title":"N-(2,6-dimethoxypyridine-3-yl)-9-methylcarbazole-3-sulfonamide as a novel tubulin ligand against human cancer","volume":"14","author":"Wang","year":"2008","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib153","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116509","article-title":"Structure-activity relationship study of new carbazole sulfonamide derivatives as anticancer agents with dual-target mechanism","volume":"273","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib154","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107738","article-title":"Scaffold overlay of flavonoid-inspired molecules: discovery of 2,3-diaryl-pyridopyrimidin-4-imine\/ones as dual hTopo-II and tubulin targeting anticancer agents","volume":"152","author":"Saini","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib155","doi-asserted-by":"crossref","first-page":"693","DOI":"10.2533\/chimia.2020.693","article-title":"DNA damaging agents in chemical biology and cancer","volume":"74","author":"Sauter","year":"2020","journal-title":"Chimia"},{"key":"10.1016\/j.ejmech.2025.118191_bib156","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/0006-2952(86)90207-8","article-title":"In vitro mechanism study of microtubule assembly inhibition by cis-dichlorodiammine-platinum(II)","volume":"35","author":"Peyrot","year":"1986","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib157","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/excr.2001.5322","article-title":"alpha-, beta-, and gamma-tubulin polymerization in response to DNA damage","volume":"270","author":"Porter","year":"2001","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib158","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1093\/jnci\/djae214","article-title":"Phase III randomized trial comparing neoadjuvant paclitaxel plus platinum with 5-fluorouracil plus platinum in esophageal or gastroesophageal junction squamous cell carcinoma","volume":"117","author":"Noronha","year":"2025","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.ejmech.2025.118191_bib159","doi-asserted-by":"crossref","first-page":"4025","DOI":"10.1038\/s41467-022-31704-7","article-title":"A randomized phase 3 trial of gemcitabine or nab-paclitaxel combined with cisPlatin as first-line treatment in patients with metastatic triple-negative breast cancer","volume":"13","author":"Wang","year":"2022","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2025.118191_bib160","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1001\/jamaoncol.2019.0001","article-title":"Japanese Gynecologic Oncology Group, Effect of taxane plus platinum regimens vs doxorubicin plus cisplatin as adjuvant chemotherapy for endometrial cancer at a high risk of progression: a randomized clinical trial","volume":"5","author":"Nomura","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib161","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1007\/s10147-022-02241-6","article-title":"Phase I\/II study of nedaplatin and nab-paclitaxel for patients with previously untreated advanced squamous cell lung cancer: kanto respiratory disease study group (KRSG) 1302","volume":"27","author":"Kasai","year":"2022","journal-title":"Int. J. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib162","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113256","article-title":"Novel diaryl-2H-azirines: antitumor hybrids for dual-targeting tubulin and DNA","volume":"214","author":"Lin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib163","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/j.tcb.2020.10.004","article-title":"Cutting, amplifying, and aligning microtubules with severing enzymes","volume":"31","author":"Kuo","year":"2021","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib164","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.devcel.2019.10.010","article-title":"Katanin grips the \u03b2-tubulin tail through an electropositive double spiral to sever microtubules","volume":"52","author":"Zehr","year":"2020","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118191_bib165","doi-asserted-by":"crossref","first-page":"4057","DOI":"10.1083\/jcb.201612104","article-title":"Microtubule-severing enzymes: from cellular functions to molecular mechanism","volume":"217","author":"McNally","year":"2018","journal-title":"J. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib166","first-page":"4963","article-title":"The role of katanin p60 in breast cancer bone metastasis","volume":"15","author":"Fu","year":"2018","journal-title":"Oncol. Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib167","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1002\/pros.21431","article-title":"Aberrant expression of katanin p60 in prostate cancer bone metastasis","volume":"72","author":"Ye","year":"2012","journal-title":"Prostate"},{"key":"10.1016\/j.ejmech.2025.118191_bib168","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1186\/s12957-020-01939-z","article-title":"Katanin p60: a potential biomarker for lymph node metastasis and prognosis for non-small cell lung cancer","volume":"18","author":"Wang","year":"2020","journal-title":"World J. Surg. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib169","doi-asserted-by":"crossref","DOI":"10.1002\/jcla.23502","article-title":"Katanin P60 and P80 in papillary thyroid carcinoma patients: indicators for exacerbated tumor features and worse disease-free survival","volume":"34","author":"Chen","year":"2020","journal-title":"J. Clin. Lab. Anal."},{"key":"10.1016\/j.ejmech.2025.118191_bib170","doi-asserted-by":"crossref","first-page":"8521","DOI":"10.1021\/acs.jmedchem.6b00797","article-title":"Purine-type compounds induce microtubule fragmentation and lung cancer cell death through interaction with katanin","volume":"59","author":"Kuo","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib171","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-83723-7","article-title":"Exploring purine analogues as inhibitors against katanin, a microtubule severing enzyme using molecular modeling approach","volume":"14","author":"Saxena","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2025.118191_bib172","doi-asserted-by":"crossref","first-page":"2524","DOI":"10.1093\/hmg\/ddn153","article-title":"LAPSER1\/LZTS2: a pluripotent tumor suppressor linked to the inhibition of katanin-mediated microtubule severing","volume":"17","author":"Sudo","year":"2008","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2025.118191_bib173","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ejmech.2019.05.072","article-title":"Design, synthesis, antitumor activities and biological studies of novel diaryl substituted fused heterocycles as dual ligands targeting tubulin and katanin","volume":"178","author":"Gao","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib174","doi-asserted-by":"crossref","first-page":"12118","DOI":"10.1021\/acs.jmedchem.4c00878","article-title":"Discovery of novel diaryl-substituted fused heterocycles targeting katanin and tubulin with potent antitumor and antimultidrug resistance efficacy","volume":"67","author":"Jiang","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib175","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.3390\/biomedicines10071757","article-title":"The thioredoxin system of mammalian cells and its modulators","volume":"10","author":"Hasan","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.ejmech.2025.118191_bib176","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/17460441.2022.2045270","article-title":"Novel strategies for targeting the thioredoxin system for cancer therapy","volume":"17","author":"Xu","year":"2022","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118191_bib177","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.122711","article-title":"Thioredoxin system in colorectal cancer: its role in carcinogenesis, disease progression, and response to treatment","volume":"348","author":"Abdullah","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib178","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1111\/cas.13279","article-title":"Suberoylanilide hydroxamic acid sensitizes neuroblastoma to paclitaxel by inhibiting thioredoxin-related protein 14-mediated autophagy","volume":"108","author":"Zhen","year":"2017","journal-title":"Cancer Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib179","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.bbadis.2014.12.002","article-title":"Thioredoxin 1 upregulates FOXO1 transcriptional activity in drug resistance in ovarian cancer cells","volume":"1852","author":"Wang","year":"2015","journal-title":"Biochim. Biophys. Acta Mol. Basis Dis."},{"key":"10.1016\/j.ejmech.2025.118191_bib180","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113897","article-title":"Structure modification and biological evaluation of indole-chalcone derivatives as anti-tumor agents through dual targeting tubulin and TrxR","volume":"227","author":"Yan","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib181","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2024.217093","article-title":"Targeting LSD1 in cancer: molecular elucidation and recent advances","volume":"598","author":"Cai","year":"2024","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib182","doi-asserted-by":"crossref","first-page":"462","DOI":"10.3390\/biom12030462","article-title":"The role of LSD1 and LSD2 in cancers of the gastrointestinal system: an update","volume":"12","author":"Malagraba","year":"2022","journal-title":"Biomolecules"},{"key":"10.1016\/j.ejmech.2025.118191_bib183","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/med.22000","article-title":"LSD1 in drug discovery: from biological function to clinical application","volume":"44","author":"Liu","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118191_bib184","doi-asserted-by":"crossref","first-page":"4275","DOI":"10.1021\/acs.jmedchem.2c01527","article-title":"Lysine-specific demethylase 1 promises to be a novel target in cancer drug resistance: therapeutic implications","volume":"66","author":"Yang","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib185","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41392-023-01341-7","article-title":"Targeting epigenetic regulators to overcome drug resistance in cancers","volume":"8","author":"Wang","year":"2023","journal-title":"Signal Transduct. Targeted Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib186","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.862427","article-title":"A phase 1 proof of concept study evaluating the addition of an LSD1 inhibitor to nab-paclitaxel in advanced or metastatic breast cancer (EPI-PRIMED)","volume":"12","author":"Prasanna","year":"2022","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib187","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115281","article-title":"Discovery of novel N-benzylarylamide-dithiocarbamate based derivatives as dual inhibitors of tubulin polymerization and LSD1 that inhibit gastric cancers","volume":"252","author":"Yuan","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib188","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114583","article-title":"Discovery of N-benzylarylamide derivatives as novel tubulin polymerization inhibitors capable of activating the hippo pathway","volume":"240","author":"Song","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib189","doi-asserted-by":"crossref","first-page":"8543","DOI":"10.1021\/jm401002r","article-title":"Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration","volume":"56","author":"Zheng","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib190","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1038\/s41417-022-00477-y","article-title":"The V-ATPases in cancer and cell death","volume":"29","author":"Chen","year":"2022","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib191","doi-asserted-by":"crossref","first-page":"1292","DOI":"10.4161\/auto.25399","article-title":"ROS-induced autophagy in cancer cells assists in evasion from determinants of immunogenic cell death","volume":"9","author":"Garg","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2025.118191_bib192","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1080\/15548627.2015.1091141","article-title":"ER stress: autophagy induction, inhibition and selection","volume":"11","author":"Rashid","year":"2015","journal-title":"Autophagy"},{"key":"10.1016\/j.ejmech.2025.118191_bib193","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1021\/acschembio.8b00656","article-title":"Previously uncharacterized vacuolar-type ATPase binding site discovered from structurally similar compounds with distinct mechanisms of action","volume":"14","author":"Wang","year":"2019","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib194","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1423-0127-18-44","article-title":"Specific microtubule-depolymerizing agents augment efficacy of dendritic cell-based cancer vaccines","volume":"18","author":"Wen","year":"2011","journal-title":"J. Biomed. Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib195","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1007\/s12272-019-01150-z","article-title":"Natural compound inducers of immunogenic cell death","volume":"42","author":"Diederich","year":"2019","journal-title":"Arch Pharm. Res. (Seoul)"},{"key":"10.1016\/j.ejmech.2025.118191_bib196","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/j.ejphar.2011.05.042","article-title":"Effects of diphyllin as a novel V-ATPase inhibitor on gastric adenocarcinoma","volume":"667","author":"Shen","year":"2011","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib197","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.1359\/jbmr.070613","article-title":"Diphyllin, a novel and naturally potent V-ATPase inhibitor, abrogates acidification of the osteoclastic resorption lacunae and bone resorption","volume":"22","author":"S\u00f8rensen","year":"2007","journal-title":"J. Bone Miner. Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib198","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1158\/1535-7163.MCT-17-1195","article-title":"Phyllanthusmin derivatives induce apoptosis and reduce tumor burden in high-grade serous ovarian cancer by late-stage autophagy inhibition","volume":"17","author":"Young","year":"2018","journal-title":"Mol. Cancer Therapeut."},{"key":"10.1016\/j.ejmech.2025.118191_bib199","doi-asserted-by":"crossref","first-page":"16774","DOI":"10.1021\/acs.jmedchem.2c01595","article-title":"Discovery of novel N-heterocyclic-fused deoxypodophyllotoxin analogues as tubulin polymerization inhibitors targeting the colchicine-binding site for cancer treatment","volume":"65","author":"Leng","year":"2022","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib200","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1021\/acs.jmedchem.3c02399","article-title":"Discovery of novel isoquinoline analogues as dual tubulin polymerization\/V-ATPase inhibitors with immunogenic cell death induction","volume":"67","author":"Leng","year":"2024","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib201","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.bcp.2015.01.005","article-title":"Tubulin-binding agents down-regulate matrix metalloproteinase-2 and -9 in human hormone-refractory prostate cancer cells\u2013a critical role of Cdk1 in mitotic entry","volume":"94","author":"Chang","year":"2015","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib202","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1124\/pharmrev.121.000349","article-title":"Matrix metalloproteinases: from molecular mechanisms to physiology, pathophysiology, and pharmacology","volume":"74","author":"de Almeida","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2025.118191_bib203","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.3390\/cells9051313","article-title":"Metalloproteinases and their inhibitors: potential for the development of new therapeutics","volume":"9","author":"Raeeszadeh-Sarmazdeh","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118191_bib204","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.colsurfb.2014.11.005","article-title":"Paclitaxel\/epigallocatechin gallate coloaded liposome: a synergistic delivery to control the invasiveness of MDA-MB-231 breast cancer cells","volume":"125","author":"Ramadass","year":"2015","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"10.1016\/j.ejmech.2025.118191_bib205","first-page":"3253","article-title":"Augmented growth inhibition of B16-BL6 melanoma by combined treatment with a selective matrix metalloproteinase inhibitor, MMI-166, and cytotoxic agents","volume":"22","author":"Hojo","year":"2002","journal-title":"Anticancer Res."},{"key":"10.1016\/j.ejmech.2025.118191_bib206","doi-asserted-by":"crossref","first-page":"3878","DOI":"10.1111\/jcmm.14242","article-title":"Therapeutic efficacy of anti-MMP9 antibody in combination with nab-paclitaxel-based chemotherapy in pre-clinical models of pancreatic cancer","volume":"23","author":"Awasthi","year":"2019","journal-title":"J. Cell Mol. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib207","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114817","article-title":"Novel combretastatin A-4 derivative containing aminophosphonates as dual inhibitors of tubulin and matrix metalloproteinases for lung cancer treatment","volume":"244","author":"Huang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib208","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2022.114439","article-title":"Dual-functional antitumor conjugates improving the anti-metastasis effect of combretastatin A4 by targeting tubulin polymerization and matrix metalloproteinases","volume":"238","author":"Yang","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib209","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2025.117249","article-title":"Discovery of novel dual tubulin and MMPs inhibitors for the treatment of lung cancer and overcoming drug resistance","volume":"285","author":"Li","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib210","first-page":"904","article-title":"Non-canonical functions of the mitotic kinesin Eg5, Thorac","volume":"9","author":"Liu","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.ejmech.2025.118191_bib211","doi-asserted-by":"crossref","DOI":"10.1155\/2024\/3649912","article-title":"Eg5 and diseases: from the well-known role in cancer to the less-known activity in noncancerous pathological conditions","volume":"2024","author":"Ricci","year":"2024","journal-title":"Biochem. Res. Int."},{"key":"10.1016\/j.ejmech.2025.118191_bib212","doi-asserted-by":"crossref","first-page":"1698","DOI":"10.3390\/cells10071698","article-title":"Eg5 as a prognostic biomarker and potential therapeutic target for hepatocellular carcinoma","volume":"10","author":"Shao","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.118191_bib213","doi-asserted-by":"crossref","first-page":"62208","DOI":"10.18632\/oncotarget.19215","article-title":"High Eg5 expression predicts poor prognosis in breast cancer","volume":"8","author":"Jin","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.ejmech.2025.118191_bib214","doi-asserted-by":"crossref","DOI":"10.1016\/j.bcp.2020.114364","article-title":"Eg5 targeting agents: from new anti-mitotic based inhibitor discovery to cancer therapy and resistance","volume":"184","author":"Garcia-Saez","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.118191_bib215","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107930","article-title":"Combretastatin A-4 based compounds as potential anticancer agents: a review","volume":"153","author":"Omar","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib216","doi-asserted-by":"crossref","first-page":"1543","DOI":"10.1038\/aps.2011.130","article-title":"Dimethylenastron suppresses human pancreatic cancer cell migration and invasion in vitro via allosteric inhibition of mitotic kinesin Eg5","volume":"32","author":"Sun","year":"2011","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.ejmech.2025.118191_bib217","doi-asserted-by":"crossref","first-page":"5676","DOI":"10.1021\/jm100421n","article-title":"Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol","volume":"53","author":"Kaan","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib218","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107449","article-title":"Discovery of novel octahydroquinazoline scaffolds endowed with dual inhibition of tubulin polymerization\/Eg5 against HCC: apoptotic and radio-chemotherapeutic studies","volume":"148","author":"Abdelhameid","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib219","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3390\/curroncol32040203","article-title":"Neuropilin-1: a multifaceted target for cancer therapy","volume":"32","author":"Varanasi","year":"2025","journal-title":"Curr. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib220","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/1061186X.2020.1815210","article-title":"New insights into the role of co-receptor neuropilins in tumour angiogenesis and lymphangiogenesis and targeted therapy strategies","volume":"29","author":"Zhao","year":"2021","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ejmech.2025.118191_bib221","doi-asserted-by":"crossref","first-page":"4922","DOI":"10.3390\/cancers15204922","article-title":"The nervous system development regulator neuropilin-1 as a potential prognostic marker and therapeutic target in brain cancer","volume":"15","author":"Rodrigues","year":"2023","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2025.118191_bib222","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41419-023-05696-1","article-title":"NRP1 promotes prostate cancer progression via modulating EGFR-dependent AKT pathway activation","volume":"14","author":"Zhang","year":"2023","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.ejmech.2025.118191_bib223","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.devcel.2016.03.015","article-title":"The complexity of translating anti-angiogenesis therapy from basic science to the clinic","volume":"37","author":"Ye","year":"2016","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2025.118191_bib224","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.ygyno.2017.01.031","article-title":"The development and use of vascular targeted therapy in ovarian cancer","volume":"145","author":"Chase","year":"2017","journal-title":"Gynecol. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib225","doi-asserted-by":"crossref","first-page":"e567","DOI":"10.1002\/onco.13612","article-title":"Phase I dose-escalation study of SCB01A, a microtubule inhibitor with vascular disrupting activity, in patients with advanced solid tumors","volume":"26","author":"Shiah","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.ejmech.2025.118191_bib226","doi-asserted-by":"crossref","first-page":"2215","DOI":"10.1021\/jm901755g","article-title":"Small molecule inhibitors of the neuropilin-1 vascular endothelial growth factor a (VEGF-A) interaction","volume":"53","author":"Jarvis","year":"2010","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib227","doi-asserted-by":"crossref","first-page":"16187","DOI":"10.1021\/acs.jmedchem.3c01572","article-title":"Discovery of a dual tubulin and neuropilin-1 (NRP1) inhibitor with potent in vivo anti-tumor activity via pharmacophore-based docking screening, structure optimization, and biological evaluation","volume":"66","author":"Zheng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib228","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116425","article-title":"Design, synthesis, and biological evaluation of novel benzimidazole derivatives as anti-cervical cancer agents through PI3K\/Akt\/mTOR pathway and tubulin inhibition","volume":"271","author":"Li","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib229","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.117058","article-title":"Synthesis, biological evaluation and mechanism study of a novel indole-pyridine chalcone derivative as antiproliferative agent against tumor cells through dual targeting tubulin and HK2","volume":"282","author":"Zheng","year":"2025","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib230","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1080\/14756366.2022.2136173","article-title":"Discovery of dual tubulin-NEDDylation inhibitors with antiproliferative activity","volume":"38","author":"Fu","year":"2023","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib231","doi-asserted-by":"crossref","first-page":"740","DOI":"10.1038\/s41580-024-00729-9","article-title":"Targeted protein degradation: from mechanisms to clinic","volume":"25","author":"Tsai","year":"2024","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2025.118191_bib232","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.tips.2023.03.003","article-title":"Targeted protein degrader development for cancer: advances, challenges, and opportunities","volume":"44","author":"Fang","year":"2023","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib233","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2024.107772","article-title":"Development of natural product-based targeted protein degraders as anticancer agents","volume":"153","author":"Chen","year":"2024","journal-title":"Bioorg. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib234","doi-asserted-by":"crossref","first-page":"214","DOI":"10.2174\/1871520620666200410082652","article-title":"Targeted protein degradation: an emerging therapeutic strategy in cancer","volume":"21","author":"Barghout","year":"2021","journal-title":"Anti Cancer Agents Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib235","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1002\/med.21992","article-title":"The new direction of drug development: degradation of undruggable targets through targeting chimera technology","volume":"44","author":"Liang","year":"2024","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2025.118191_bib236","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nrd.2016.211","article-title":"Induced protein degradation: an emerging drug discovery paradigm","volume":"16","author":"Lai","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118191_bib237","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1021\/acs.biochem.4c00577","article-title":"Journey of PROTAC: from bench to clinical trial and beyond","volume":"64","author":"Berkley","year":"2025","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2025.118191_bib238","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41571-023-00736-3","article-title":"Protein degraders enter the clinic - a new approach to cancer therapy","volume":"20","author":"Chirnomas","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ejmech.2025.118191_bib239","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116067","article-title":"Discovery of the cereblon-recruiting tubulin PROTACs effective in overcoming taxol resistance in vitro and in vivo","volume":"265","author":"Yang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib240","doi-asserted-by":"crossref","first-page":"10917","DOI":"10.1021\/acs.jmedchem.3c00736","article-title":"Small-molecule hydrophobic tagging: a promising strategy of druglike technology for targeted protein degradation","volume":"66","author":"Xie","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib241","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115741","article-title":"Hydrophobic tag-based protein degradation: development, opportunity and challenge","volume":"260","author":"He","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib242","doi-asserted-by":"crossref","DOI":"10.1016\/j.cclet.2023.109192","article-title":"Hydrophobic tag tethering degrader as a promising paradigm of protein degradation: past, present and future perspectives","volume":"35","author":"Ha","year":"2024","journal-title":"Chin. Chem. Lett."},{"key":"10.1016\/j.ejmech.2025.118191_bib243","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1007\/s40265-021-01479-0","article-title":"Tirbanibulin: first approval","volume":"81","author":"Markham","year":"2021","journal-title":"Drugs"},{"key":"10.1016\/j.ejmech.2025.118191_bib244","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116458","article-title":"Design, synthesis and biological evaluation of novel tubulin-targeting agents with a dual-mechanism for polymerization inhibition and protein degradation","volume":"272","author":"Wang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib245","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116265","article-title":"Structure-based design and synthesis of BML284 derivatives: a novel class of colchicine-site noncovalent tubulin degradation agents","volume":"268","author":"Zhang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib246","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/0009-2797(91)90055-C","article-title":"Selenium: inhibition of microtubule formation and interaction with tubulin","volume":"79","author":"Leynadier","year":"1991","journal-title":"Chem. Biol. Interact."},{"key":"10.1016\/j.ejmech.2025.118191_bib247","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.freeradbiomed.2018.05.001","article-title":"Organic selenium compounds as potential chemotherapeutic agents for improved cancer treatment","volume":"127","author":"Gandin","year":"2018","journal-title":"Free Radical Biol. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib248","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113621","article-title":"Small molecule selenium-containing compounds: recent development and therapeutic applications","volume":"223","author":"Chuai","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib249","doi-asserted-by":"crossref","first-page":"11094","DOI":"10.1021\/acs.jmedchem.3c00465","article-title":"Identification of novel dual-target estrogen receptor \u03b1 degraders with tubulin inhibitory activity for the treatment of endocrine-resistant breast cancer","volume":"66","author":"Deng","year":"2023","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib250","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.115883","article-title":"Design, synthesis and biological evaluation of N-benzylaryl cinnamide derivatives as tubulin polymerization inhibitors capable of promoting YAP degradation with potent anti-gastric cancer activities","volume":"262","author":"Fu","year":"2023","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib251","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2023.116118","article-title":"Design, synthesis and biological evaluation of 1,2,3-triazole benzothiazole derivatives as tubulin polymerization inhibitors with potent anti-esophageal cancer activities","volume":"265","author":"Wu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.118191_bib252","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41591-024-03434-4","article-title":"Artificial intelligence in drug development","volume":"31","author":"Zhang","year":"2025","journal-title":"Nat. Med."},{"key":"10.1016\/j.ejmech.2025.118191_bib253","doi-asserted-by":"crossref","first-page":"5685","DOI":"10.2147\/DDDT.S509769","article-title":"Artificial intelligence-driven innovations in oncology drug discovery: transforming traditional pipelines and enhancing drug design","volume":"19","author":"Albani","year":"2025","journal-title":"Drug Des. Dev. Ther."},{"key":"10.1016\/j.ejmech.2025.118191_bib254","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1080\/17460441.2024.2367014","article-title":"Artificial intelligence for small molecule anticancer drug discovery","volume":"19","author":"Duo","year":"2024","journal-title":"Expet Opin. Drug Discov."},{"key":"10.1016\/j.ejmech.2025.118191_bib255","doi-asserted-by":"crossref","DOI":"10.3390\/ijms242216325","article-title":"CRISPR\/Cas9-mediated genome editing in cancer therapy","volume":"24","author":"Ding","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ejmech.2025.118191_bib256","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3390\/biology13080555","article-title":"Therapeutic target identification and drug discovery driven by chemical proteomics","volume":"13","author":"Zou","year":"2024","journal-title":"Biology"}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009560?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425009560?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T08:08:12Z","timestamp":1773130092000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425009560"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":256,"alternative-id":["S0223523425009560"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118191","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Tubulin-based dual-target compounds and protein degraders for cancer therapy\u2014An updated review (2021-present)","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.118191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"118191"}}